10/09/2026
Clinical success is a milestone. Commercial scalability is a different test.
Does the founder still have to fly in when hospital five goes live?
In our latest analysis, Mans International examines three depression-technology cases across China, the United States, and France, revealing three critical commercialization hurdles:
• Regulatory approval ≠ Repeatable deployment. Early success can conceal costly implementation dependencies.
• Prescription ≠ Adoption or payment. Physician prescriptions, patient activation, and reimbursement operate through different pathways.
• Clinical efficacy ≠ Operational readiness. Promising technology can struggle when real-world clinical workflows cannot accommodate it.
Through a four-stakeholder lens—patient, clinician, institution, and payer—we examine why early traction can mask structural weaknesses and why defining clear failure conditions before expansion protects capital.
At Mans International, we help technology founders and investors assess scenario maturity, identify commercialization barriers, and build strategies for sustainable, scalable growth.
The real test isn't whether hospital one works. It's whether hospital five can succeed without extraordinary founder intervention.
Read the full analysis and connect with us to explore your next commercialization decision.
https://mansinternational.net/depression-tech-stalls-after-approval/